

## DGOP/ESOP: 2nd Polish-German annual conference for oncology pharmacy "Therapy for practice"

Dr. Andrea Liekweg, Professor Slawomir Lipski, Klaus Meier



A novelty of this symposium was the presentation of case reports from daily practice by two German pharmacists with extensive experience in oncology pharmacy, Matthias Wriedt, Hamburg and Beatrix Ulrich, Bad Säckingen. Both cases illustrated possible pharmaceutical interventions.

Beatrix Ulrich presented the case of a 39 year old female patient with ovarian cancer who had been helped by intensive pharmaceutical interdisciplinary support during the process of diagnosis. Ulrich emphasized the importance of educating the patient regarding the drug therapy and providing the treating physician with information, in this case for antiemetic drug treatment. Matthias Wriedt illustrated how important pharmacist support is even in complex cancer pathologies. He presented the case of a 38 year old male patient with a rare highly malignant B-cell lymphoma. The patient benefited greatly from the pharmaceutical care he received throughout his therapy. Wriedt highlighted the need for documentation. When assisting a patient over a long period it is important to keep track of the therapeutic development according to the SOAP (Subjective, Objective, Assessment, Plan) method. Both speakers stressed the importance of the pharmacist's role as drug therapy consultant to the

The 2nd Polish-German Annual Conference for Oncology Pharmacy took place on June 3–4, 2005 in the European University City of Frankfurt/Oder–Słubice and was attended by 130 participants from Germany and Poland. The meeting was organized jointly by the Polish Pharmacy Association and DGOP/ESOP.

patient and the medical team. Both speakers encouraged pharmacists to take responsibility for their patients and contribute to their care in an interdisciplinary team.

New information was presented about current advances in radiotherapy and chemotherapy of cancer (*Mikićuk-Olasik E., Łódź; Wagner W., Osnabrück; Boss J., Münster*), errors in cancer therapy (*Justus H., Ludwigslust*), and practical aspects of pharmaceutical care of cancer patients (*Grześkowiak E., Poznań; Liekweg A., Hamburg*).

The meeting also addressed cooperation when using off-label anticancer drugs and how to disseminate knowledge of their actions. Unlicensed drugs are often prescribed in oncology for their mechanism of action and properties in order to overcome tumour resistance to chemotherapy. As costs are high, there is pressure to limit or even discontinue their use in Poland (<http://www.gazeta.pl>). The central distribution of drugs by National Health Fund (NFZ) is insufficient and in many hospitals there is no money for pivotal drugs. The patient has to pay for the expensive drugs or the medical staff has to decide who will or will not be treated. In Germany, reimbursement by insurance companies has also been reduced by the expert group (Expert group off-label <http://www.bfam.de/de/Arzneimittel/offlabel/index.php>).

The reduction of serious drug-associated adverse drug reactions (ADRs) is also an important task (*Ludwig W.D., Berlin*). The use of genetic tests to determine variations of the cellular therapeutic targets (*Niwiński P., Wrocław*) or gene expression profiling by

DNA microarray (bio-chips) (*Lipski S., Warszawa*) may predict the expected therapeutic response, may reduce the risk of therapy (ADRs) and may limit the cost of drugs.

Insights into those complex mechanisms enable researchers to develop new treatment strategies. Such new strategies will be more targeted to the individual compared to conventional chemotherapy. As examples Lipski outlined future gene therapy, as well as groups of drugs that are already internationally licensed, such as Vascular Endothelial Growth Factor (VEGF) inhibitors. The variety of future therapeutic options which Lipski presented clarified the great challenge for oncology pharmacists to contribute to tailor made antineoplastic therapies for their patients.

However the high cost of oligonucleotide arrays (150 US\$ per chip) and technical difficulties are still major obstacles to the widespread use of genetic tests. The application of tests to determine the usefulness of off-label drugs for individuals will be a subject for future consideration.

All 130 participants from Germany and Poland left this meeting with renewed understanding and friendship. This is what we need for the further development of Europe!

### Author for Correspondence

Klaus Meier

President of DGOP and ESOP  
Landesbetrieb Krankenhäuser (LBK) Hamburg GmbH  
Allgemeines Krankenhaus St. Georg  
Lohmühlenstraße 5  
D-20099 Hamburg, Germany  
KHMeier@t-online.de

# Congress Report

## Congress Report

### References

#### Centralized production

1. Allwood M. C.

Practical Guides I: Central Intravenous Additive Services

Journal of Clinical Pharmacy and Therapeutics, 1994, 19: 137-145

2. Armour D. J., et al.

The Economics of a Pharmacy-Based Central Intravenous Additive Service for Paediatric Patients  
PharmacoEconomics, October 1996, 10 (4): 386-394

3. ASHP Council on Professional Affairs

ASHP Technical Assistance Bulletin on Quality Assurance for Pharmacy-Prepared Sterile Products  
American Journal of Hospital Pharmacy, November 1993, 50: 2386-98

4. Bates D. W., Cousins D. D., Flynn E., Gosbee J. W., Richason L., Schneider P. J.

Consensus Development Conference Statement on the Safety of Intravenous Drug Delivery Systems: Balancing Safety and Cost  
Hospital Pharmacy, February 2000, Volume 35 (2): 150-5

5. Breckenridge A., Woolfson A. M. J.  
Drugs and Intravenous Fluids

British Medical Journal, September 15, 1984, 289: 637-8

6. Brier K. L.

Evaluating Aseptic Technique of Pharmacy Personnel  
American Journal of Hospital Pharmacy, March 1983, 40: 400-3

7. Chan R., Ryan M., Moriarty S., Feely J., Sabra K.

The Impact of a Centralized Reconstitution of Intravenous Additives Service on Administration Times of Intravenous Antibiotics

Eur. J. Hosp. Pharm., 1993, 3 (3): 93-95

8. Clark C.

Centralised IV Additive Services – Better Control for Pharmacies ?

British Journal of Pharmaceutical Practice, November 1988: 502-504

9. Clark C. M., Bailie G. R., Whitaker A. M., Goldberg L. A.

Parenteral Drug Delivery – Value for Money ?

The Pharmaceutical Journal, April 12, 1986: 453-455

10. Cousins D.

CIVA Services Come of Age

The Pharmaceutical Journal, June 9, 1990: HS30-31

11. Davey P., Dodd T., Kerr S., Malek M.

Audit of IV Antibiotic Administration

The Pharmaceutical Journal, June 30, 1990: 793-796

12. Deeb E. N., Natsios G. A.

Contamination of Intravenous Fluids by Bacteria and Fungi during Preparation and Administration

American Journal of Hospital Pharmacy, October 1971, 28: 764-7

13. Foltyn Smith C., Amen R. J.

Comparison of Seven Methods of Preparing and Administering Small-Volume Injections

American Journal of Hospital Pharmacy, September 1988, 45: 1896-1901

14. Francke D. E.

Intravenous Additives, Polypharmacy and Patient Safety

Drug Intelligence, June 1968, 2: 143

15. Harbarth S., Sudre P., Dharan S., Cadenas M., Pittet D.

Outbreak of Enterobacter Cloacae Related to Understaffing, Overcrowding, and Poor Hygiene Practices

Infection Control and Hospital Epidemiology, September 1999, 20 (9): 598-603

16. Hoppe-Tichy T., Noe-Schwenn S., Wahlig A., Taxis K.

Medication Errors in Parenteral Drug Administration, A Contribution to Quality Assurance on the Ward

Translated Reprint from Krankenhauspharmazie, 2002, n° 1, 11-17

17. Hull A. P.

Use of Premixed Frozen Small-Volume Injections in a Small Community Hospital

American Journal of Hospital Pharmacy, September 1990, 47: 2072-3

18. Lustig A.

Cost Evaluation of a New IV Device in an Israeli Hospital

Eur. J. Clin. Pharmacol., 1994, 47: 203-206

19. Lustig A.

A Centralized Intravenous Additive System in an Israeli Government Hospital

Israel J. Med. Sci., February-March 1993, 29 (2-3): 89-93

20. Morgan E., Fincher J. H., Sadik F., Mikeal R. L.

Evaluation of Laminar Air Flow and Nursing Station Environments for the Preparation of Intravenous Admixtures

American Journal of Hospital Pharmacy, December 1972, 29: 1020-1024

21. Morris W. E.

Parenteral Fluids and the Hospital Pharmacist

Hospital Pharmacy, 1967, 2 (11): 19-23

22. Patterson T. R., Nordstrom K. A.

An Analysis of Intravenous Additive Procedures on Nursing Units

American Journal of Hospital Pharmacy, March 1968, 25: 134-7

23. Plumridge R. J., Maher M.

Justification of a Pharmacy Intravenous Admixture Service in an Australian Hospital

American Journal of Hospital Pharmacy, March 1993, 50: 463-466

24. Prendeville N. M., O'Shea J.

Setting Up a Central Intravenous Additive Service

Irish Pharmacy Journal, July 1990: 271-276

25. Rosenthal V. D., Guzman S., Migone O., Cmich C. J.

The Attributable Cost, Length of Hospital Stay, and Mortality of Central Line-Associated Bloodstream Infection in Intensive Care Departments in Argentina: A Prospective, Matched Analysis  
AJIC, December 2003, 31 (8): 475-80

26. Rosenthal V. D., Guzman S., Cmich C.

Device-Associated Nosocomial Infection Rates in Intensive Care Units of Argentina  
Infection Control and Hospital Epidemiology, March 2004, 25 (3): 251-5

27. Rosenthal V. D., Maki D. G.

Prospective Study of the Impact of Open and Closed Infusion Systems on Rates of Central Venous Catheter-Associated Bacteremia  
AJIC, May 2004, 32 (3): 135-41

28. Rosenthal V. D., et al.

Effect of an Infection Control Program using Education and Performance Feedback on Rates of Intravascular Device-Associated Bloodstream Infections in Intensive Care Units in Argentina  
AJIC, November 2003, 31 (7): 405-9

29. Rosenthal V. D., et al.

Nosocomial Infections in Medical-Surgical Intensive Care Units in Argentina : Attributable Mortality and Length of Stay  
Am J Infect Control, August 2003, 31 (5): 291-5

30. Skolaut M. W.

Long-Term Benefits of a Centralized I.V. Additive Service

American Journal of Hospital Pharmacy, September 1968, 25: 536-7

31. Taxis K., Barber N.

Ethnographic Study of Incidence and Severity of Intravenous Drug Errors  
BMJ, March 29, 2003, 326: 1-4

32. Wakefield D. S., Pfaller M. A., Hammons G. T., Massanari R. M.

Use of the Appropriateness Evaluation Protocol for

Estimating the Incremental Costs Associated with Nosocomial Infections  
Medical Care, June 1987, 25 (6): 481-8

**Pharmaceutical industry. Antibiotics and hazards for the worker.**

33. Davies RJ, Hendrick DJ, Pepys J.

Asthma due to inhaled chemical agents: ampicillin, benzyl penicillin, 6 amino penicillanic acid and related substances.

Clin Allergy. 1974 Sep;4(3):227-47.

34. Davies RJ, Pepys J

Asthma due to inhaled chemical agents – the macrolide antibiotic Spiramycin

Clin Allergy. 1975 Mar;(1):99-107.

35. Coutts II, Dally MB, Taylor AJ, Pickering CA, Horsfield N.

Asthma in workers manufacturing cephalosporins

Br Med J. 1981 Oct 10; 283(6297):950.

36. Moscato G, Galdi E, Scibilia J, Dellabianca A, Omodeo P, Vittadini G, Biscaldi GP

Occupational asthma, rhinitis and urticaria due to piperacillin sodium in pharmaceutical worker:

Eur Respir J. 1995 Mar;8(3):467-9

37. Stenton SC, Dennis JH, Hendrick DJ

Occupational asthma due to ceftazidime

Eur Respir J. 1995 Aug;8(8):1421-3

38. Sastre J, Quirce S, Novalbos A, Lluich-Bernal M,

Bombin C, Umpierrez A.

Occupational asthma induced by cephalosporins

Eur Respir J. 1999 May; 13(5):1189-91

39. Kiffmeyer TK, Kube C, Opiolka S, Schmidt, KG, Schöppe G, Sessink PJ

Vapour pressures, evaporation behaviour and airborne concentrations of hazardous drugs: implications for occupational safety.

The Pharmaceutical Journal, 2002 vol. 268 March; 332-337

40. Nicholas S, Brown D, Short C

Evaluation of the Baxter Minibag Plus for ward preparation of cefuroxime/metronidazole infusion mixtures

Hospital Pharmacist 2000 Nov; 297-300